Literature DB >> 1621772

Albright hereditary osteodystrophy with hypothyroidism, normocalcemia, and normal Gs protein activity: a family presenting with congenital osteoma cutis.

S Izraeli1, A Metzker, G Horev, D Karmi, P Merlob, Z Farfel.   

Abstract

The syndrome of Albright hereditary osteodystrophy (AHO), pseudohypoparathyroidism (PHP) and pseudopseudohypoparathyroidism (PPHP) is clinically and genetically heterogeneous. Classically, patients with PHP have the skeletal features of AHO, resistance to multiple hormones that work via cAMP such as parathyroid hormone and thyroid stimulating hormone, and deficient activity of Gs protein, the guanine nucleotide-binding protein that stimulates adenylate cyclase. However, patients without hormone resistance but with AHO and Gs deficiency were described (PPHP), as well as patients with multiple hormone resistance but without AHO or Gs deficiency. In a few patients with deficient Gs activity, hypothyroidism rather than hypocalcemia was the initial presentation of the disorder. We describe here a new variant of the syndrome, affecting 5 individuals in a 3 generation family with AHO, normal Gs activity and hypothyroidism. In the first 2 generations, mild features of AHO were present. The 2 sibs in the third generation had severe manifestations of AHO, including mild mental retardation as well as hypothyroidism. Diagnosis of congenital osteoma cutis at birth of the proband led to the diagnosis of the family. Elucidation of the molecular defect will shed light on the relationship between hormone resistance and AHO, as well as on the physiological mechanism of hormonal signal transduction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621772     DOI: 10.1002/ajmg.1320430424

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  7 in total

Review 1.  Clinical spectrum and pathogenesis of pseudohypoparathyroidism.

Authors:  M A Levine
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Imprinting in Albright's hereditary osteodystrophy.

Authors:  S J Davies; H E Hughes
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

Review 3.  Aberrant Bone Regulation in Albright Hereditary Osteodystrophy dueto Gnas Inactivation: Mechanisms and Translational Implications.

Authors:  Patrick McMullan; Emily L Germain-Lee
Journal:  Curr Osteoporos Rep       Date:  2022-02-28       Impact factor: 5.096

Review 4.  GNAS mutations and heterotopic ossification.

Authors:  Murat Bastepe
Journal:  Bone       Date:  2017-09-06       Impact factor: 4.398

5.  A patient with features of albright hereditory osteodystrophy and unusual neuropsychiatric findings without coding Gsalpha mutations.

Authors:  Shirin Hasani-Ranjbar; Zahra Jouyandeh; Mahsa Mohammad Amoli; Akbar Soltani; Seyed Masoud Arzaghi
Journal:  J Diabetes Metab Disord       Date:  2014-05-22

6.  Ectopic calcification as discernible manifestation in neonates with pseudohypoparathyroidism type 1a.

Authors:  Masanori Adachi; Koji Muroya; Yumi Asakura; Yoichi Kondoh; Jun Ishihara; Tomonobu Hasegawa
Journal:  Int J Endocrinol       Date:  2009       Impact factor: 3.257

Review 7.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.